Impact of ureteroscopy before nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes Journal Article


Authors: Sankin, A.; Tin, A. L.; Mano, R.; Chevinsky, M.; Jakubowski, C.; Sfakianos, J. P.; Cha, E. K.; Yee, A.; Friedman, F. M.; Sjoberg, D. D.; Ehdaie, B.; Coleman, J.
Article Title: Impact of ureteroscopy before nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes
Abstract: Objective To compare the oncologic outcomes of patients with upper tract urothelial carcinoma undergoing nephroureterectomy (NU) with and without prior ureteroscopy (URS). Methods We reviewed records of all patients with no prior history of bladder cancer who underwent NU at our institution (n = 201). We compared patients who underwent URS before NU with patients who proceeded directly to NU based on imaging alone. After excluding patients undergoing URS with therapeutic intent, we used multivariable Cox proportional hazards models, adjusting for tumor characteristics with cancer-specific survival (CSS), intravesical recurrence-free survival, metastasis-free survival (MFS), and overall survival (OS) as end points. This study received institutional review board approval. Results A total of 144 (72%) patients underwent URS before NU, and 57 (28%) patients proceeded directly to NU. The median follow-up time for survivors was 5.4 years from diagnosis. The performance of diagnostic URS before NU was significantly associated with IR (hazard ratio 2.58; 95% CI 1.47, 4.54; P = .001), although it was not associated with CSS, MFS, or OS. The adjusted intravesical recurrence-free survival probability 3 years after diagnosis is 71% and 42% for patients who did not and did receive URS before NU, respectively (adjusted risk difference 30%; 95% CI 13%, 47%). Conclusion We did not find evidence that URS adversely impacts disease progression and survival in patients with upper tract urothelial carcinoma. Although patients are at higher risk for IR after NU when they have undergone prior diagnostic URS, their CSS, MFS, and OS are not significantly affected. © 2016 Elsevier Inc.
Journal Title: Urology
Volume: 94
ISSN: 0090-4295
Publisher: Elsevier Science, Inc.  
Date Published: 2016-08-01
Start Page: 148
End Page: 153
Language: English
DOI: 10.1016/j.urology.2016.05.039
PROVIDER: scopus
PUBMED: 27237781
PMCID: PMC5114126
DOI/URL:
Notes: Article -- Export Date: 2 November 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Coleman
    341 Coleman
  2. Daniel D. Sjoberg
    234 Sjoberg
  3. Behfar Ehdaie
    173 Ehdaie
  4. Roy Mano
    52 Mano
  5. Eugene K. Cha
    99 Cha
  6. Amy Lam Ling Tin
    114 Tin